Loading... Please wait...
Sort by:

 

FirstView NPS+

An expanded view of brand loyalty among doctors

Actionable metrics to help you make better brand decisions

 

Net Promoter Score (NPS) is an easy way to measure brand health, but it doesn’t tell you how to improve it. NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty

 

Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.

 

Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.

  • Medical Affairs Reputations: Cancer Pain (US) 2017
    Learn More Medical Affairs Reputations: Cancer Pain (US) 2017
    Disappointing scores show that medical affairs teams need to up their game The medical oncologists we surveyed say that medical affairs teams for cancer pain drugs turned in a lacklustre performance in the past 6 months...
  • NPS+ Melanoma (EU5) 2017
    Learn More NPS+ Melanoma (EU5) 2017
    Leading melanoma treatments may have a differentiation problem Two melanoma treatments are comfortably ahead of the pack in the EU5, earning by far the highest satisfaction scores from medical oncologists. Can either...
  • NPS+ Melanoma (US) 2017
    Learn More NPS+ Melanoma (US) 2017
    Is lack of experience hurting doctors’ perceptions of your brand? Lack of experience may be keeping two melanoma treatments from earning higher satisfactions scores. Results of our survey show that US-based...
  • NPS+ Asthma/COPD (EU5) 2017
    Learn More NPS+ Asthma/COPD (EU5) 2017
    Is there a loyalty issue for the leading asthma/COPD brands in Europe? With so many mono and combination therapies on offer to treat asthma and COPD, how is an abundance of choice impacting brand loyalty? What do...
  • NPS+ Asthma/COPD (US) 2017
    Learn More NPS+ Asthma/COPD (US) 2017
    Is there a loyalty issue for the leading asthma/COPD brands in the US?  With so many mono and combination therapies on offer to treat asthma and COPD, how is an abundance of choice impacting brand loyalty? What do...
  • Medical Affairs Reputations: HIV (EU5) 2017
    Learn More Medical Affairs Reputations: HIV (EU5) 2017
    Targeted improvements could help your medical affairs team win over doctors The infectious disease specialists we surveyed say medical affairs teams for 9 major HIV treatments could be doing a better job. They...
  • Medical Affairs Reputations: HIV (US) 2017
    Learn More Medical Affairs Reputations: HIV (US) 2017
    Survey shows medical affairs teams must be more active and provide better information Doctors say medical affairs teams for 10 major HIV treatments could be doing a better job. In the past 6 months, only one of those...
  • Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2017
    Learn More Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2017
    Better information provision could give your medical affairs team a boost with doctors Is your medical affairs team giving doctors the information they need? Maybe not, according to our survey of 100 medical oncologists...
  • Medical Affairs Reputations: Renal Cell Carcinoma (US) 2017
    Learn More Medical Affairs Reputations: Renal Cell Carcinoma (US) 2017
    Better information provision could give your medical affairs team a boost with doctors Is your medical affairs team giving doctors the information they need? Maybe not, according to our survey of 100 medical oncologists...
  • NPS+ Psoriasis 2017 (EU)
    Learn More NPS+ Psoriasis 2017 (EU)
    Biosimilars take the biggest hit as doctors voice dissatisfaction with psoriasis treatments Dermatologists say they’re satisfied with available psoriasis treatments. So why did only 3 of the brands we asked them...
  • NPS+ Psoriasis 2017 (US)
    Learn More NPS+ Psoriasis 2017 (US)
    Two psoriasis treatments get a thumbs-down from otherwise satisfied doctors Dermatologists may be happy with psoriasis treatments overall, but they gave dismal satisfaction scores to 2 of the 8 brands we surveyed them...
  • NPS+ HIV (US) 2017
    Learn More NPS+ HIV (US) 2017
    Doctors upbeat about HIV treatments, but satisfaction runs highest for 3 brands Doctors may be satisfied with available HIV treatments overall, but when we surveyed 100 US-based infectious disease specialists and...
  • NPS+ HIV (EU5) 2017
    Learn More NPS+ HIV (EU5) 2017
    Doctors upbeat about HIV treatments, but satisfaction runs highest for 2 brands Doctors may be satisfied with available HIV treatments overall, but when we surveyed 150 EU5-based infectious disease specialists and...
  • NPS+ Renal Cell Carcinoma (EU5) 2017
    Learn More NPS+ Renal Cell Carcinoma (EU5) 2017
    How ‘healthy’ are brand loyalty and satisfaction levels amongst RCC oncologists? According to this latest survey, the top three ‘healthiest’ Renal Cell Carcinoma (RCC) brands in Europe with the...
  • NPS+ Renal Cell Carcinoma (US) 2017
    Learn More NPS+ Renal Cell Carcinoma (US) 2017
    How ‘healthy’ are brand loyalty and satisfaction levels amongst RCC oncologists? With some relatively recent entrants gaining ground amongst a field of established drugs, how is brand loyalty faring across...
  • NPS+ Parkinson’s Disease (EU5) 2017
    Learn More NPS+ Parkinson’s Disease (EU5) 2017
    Low scores for 7 of 8 surveyed brands reflect widespread dissatisfaction among doctors Neurologists in the EU5 countries are not happy with available Parkinson’s disease treatments, and it shows. According to our...

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved